Eli Lilly Says 'Vitriol' Behind Teva's Bid To Triple IP Verdict
By Elliot Weld · March 2, 2023, 4:46 PM EST
Eli Lilly & Co. has pushed back on rival Teva Pharmaceuticals' request to triple a $176.5 million migraine drug patent infringement verdict, saying Teva's motion resorted to "vitriol" by misconstruing the...
To view the full article, register now.